Evidence map›Paper›PMID 38939513›Full record

ArticleLeukemia research reports2024

Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma.

Yoshikazu Hori, Hiroki Hosoi, Toshiki Mushino, Yuka Okabe, Ayaka Sakaki, Kikuaki Yoshida, Yuichi Tochino, Yusuke Yamashita, Takashi Sonoki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yoshikazu HoriDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Hiroki HosoiDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Toshiki MushinoDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Yuka OkabeDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Ayaka SakakiDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Kikuaki YoshidaDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Yuichi TochinoDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Yusuke YamashitaDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Takashi SonokiDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preventing central nervous system (CNS) relapse is a major challenge in the treatment of diffuse large B-cell lymphoma (DLBCL). However, no previous studies have examined the efficacy of polatuzumab vedotin (PV)-containing regimens in preventing CNS relapse in patients with DLBCL. Here, we report two cases of CNS relapse after PV-containing chemotherapy for DLBCL. CNS relapse developed during combination therapy with PV, bendamustine, and rituximab (PV-BR) in one patient and six months after PV-BR in the other patient. PV-containing chemotherapy may be ineffective as a prophylaxis against CNS relapse; therefore, additional strategies for preventing CNS relapse in DLBCL patients are required.

Indexed as

Central nervous system relapseDiffuse large B-cell lymphomaPolatuzumab vedotin

Identifiers

PMID38939513
PMCPMC11208936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.